Sun Pharmaceutical Industries

Shares of Sun Pharmaceutical Industries fell by over 4 per cent in morning trade on Tuesday a day after the company said its consolidated net loss stood at Rs 2,277 crore for the fourth quarter ended March 2022, mainly on account of a one-time exceptional loss.

Sun Pharmaceutical Industries on Monday said its consolidated net loss stood at Rs 2,277 crore for the fourth quarter ended March 2022

Pharma Stocks Today: Pharmaceutical shares such as Cipla, Dr Reddy's Laboratories, Torrent Pharma, Sun Pharma Industries gained around two per cent each on Wednesday

Merck & Co Inc said on Tuesday it had partnered with five Indian generic drugmakers, including Cipla Ltd and Sun Pharmaceutical Industries Ltd, to expand production and access to its experimental COVID-19 drug.

Pharmaceutical stocks today: On Friday, Cipla opened on the NSE at Rs 840.90, touching an intra day high of Rs 892.30 and an intra day low of Rs 836.65, in the session so far

The pharmaceutical market reported 128.3 billion total sales in November 2020 and decline in volume can be attributed to the lower sales of the acute therapy products

Sun Pharmaceutical Industries has said it has launched Favipiravir (200 mg) in India under the brand FluGuard at an economical price of Rs 35 per tablet for the treatment of mild to moderate cases of COVID-19.

Aquinox Pharmaceuticals is a research and development company focused on pharmaceutical products for the purpose of their commercialisation, Sun Pharma said.

Domestic stock markets started Monday's session on a higher note amid gains in Asian peers. The S&P BSE Sensex index rose as much as 313.54 points to touch 37,663.87 in early trade, and the broader NSE Nifty benchmark moved to 11,129.85, up 82.05 points from the previous close. Buying in financial, information technology and pharmaceuticals sectors...

Sun Pharma shares price today jumped more than 4 per cent in intraday trade. Sun Pharma the previous day reported a nearly four-fold increase in quarterly net profit. Sun Pharma said it had incurred a one-time tax expense of Rs 513 crore - related to changes in US tax rates - in the year-ago period.

Sun Pharmaceutical Industries' total revenue from operations grew 16.3 per cent to Rs 7740 crore.

The US FDA conducted inspection at Sun Pharmaceutical Industries' facility in Halol from February 12 to February 23.

The S&P BSE Sensex on Friday were 19.41 points down and closed at 35,443.67. The National Stock Exchange (NSE) benchmark index Nifty50 settled at 10,767.65. Stock markets edged lower today after two straight sessions of gains. Markets witnessed a volatile trading during the day. Stock markets largely ended flat as losses in both indexes on account...

Pharma stocks pushed both indexes lower, with the Nifty Pharma index falling over 1 per cent. Sun Pharmaceutical Industries fell over 3 per cent.

Shares of Sun Pharmaceutical Industries on Wednesday ended 4 per cent lower after the company reported a 59.19 per cent decline in consolidated net profit

Shares of Sun Pharmaceutical Industries fell by over 4 per cent in morning trade on Tuesday a day after the company said its consolidated net loss stood at Rs 2,277 crore for the fourth quarter ended March 2022, mainly on account of a one-time exceptional loss.

Sun Pharmaceutical Industries on Monday said its consolidated net loss stood at Rs 2,277 crore for the fourth quarter ended March 2022

Pharma Stocks Today: Pharmaceutical shares such as Cipla, Dr Reddy's Laboratories, Torrent Pharma, Sun Pharma Industries gained around two per cent each on Wednesday

Merck & Co Inc said on Tuesday it had partnered with five Indian generic drugmakers, including Cipla Ltd and Sun Pharmaceutical Industries Ltd, to expand production and access to its experimental COVID-19 drug.

Pharmaceutical stocks today: On Friday, Cipla opened on the NSE at Rs 840.90, touching an intra day high of Rs 892.30 and an intra day low of Rs 836.65, in the session so far

The pharmaceutical market reported 128.3 billion total sales in November 2020 and decline in volume can be attributed to the lower sales of the acute therapy products

Sun Pharmaceutical Industries has said it has launched Favipiravir (200 mg) in India under the brand FluGuard at an economical price of Rs 35 per tablet for the treatment of mild to moderate cases of COVID-19.

Aquinox Pharmaceuticals is a research and development company focused on pharmaceutical products for the purpose of their commercialisation, Sun Pharma said.

Domestic stock markets started Monday's session on a higher note amid gains in Asian peers. The S&P BSE Sensex index rose as much as 313.54 points to touch 37,663.87 in early trade, and the broader NSE Nifty benchmark moved to 11,129.85, up 82.05 points from the previous close. Buying in financial, information technology and pharmaceuticals sectors...

Sun Pharma shares price today jumped more than 4 per cent in intraday trade. Sun Pharma the previous day reported a nearly four-fold increase in quarterly net profit. Sun Pharma said it had incurred a one-time tax expense of Rs 513 crore - related to changes in US tax rates - in the year-ago period.

Sun Pharmaceutical Industries' total revenue from operations grew 16.3 per cent to Rs 7740 crore.

The US FDA conducted inspection at Sun Pharmaceutical Industries' facility in Halol from February 12 to February 23.

The S&P BSE Sensex on Friday were 19.41 points down and closed at 35,443.67. The National Stock Exchange (NSE) benchmark index Nifty50 settled at 10,767.65. Stock markets edged lower today after two straight sessions of gains. Markets witnessed a volatile trading during the day. Stock markets largely ended flat as losses in both indexes on account...

Pharma stocks pushed both indexes lower, with the Nifty Pharma index falling over 1 per cent. Sun Pharmaceutical Industries fell over 3 per cent.

Shares of Sun Pharmaceutical Industries on Wednesday ended 4 per cent lower after the company reported a 59.19 per cent decline in consolidated net profit